US · ICLR · MEDICAL - DIAGNOSTICS & RESEARCH
ICON Public Limited Company (ICLR) intrinsic value and stock valuation
$186.71as of 2026-11-21 · Mkt cap 12.6B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ICON Public Limited Company DCF and intrinsic value
InvestorsCraft values ICLR with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ICLR’s statements →
ICON Public Limited Company Graham Number
Graham Number: $87.83d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Guardant Health, Inc. (GH) $145.83
- Medpace Holdings, Inc. (MEDP) $610.54
- Neurocrine Biosciences, Inc. (NBIX) $150.57
- The Cooper Companies, Inc. (COO) $58.88
- Solventum Corporation (SOLV) $84.50
- Revvity, Inc. (RVTY) $145.22
- Encompass Health Corporation (EHC) $133.65
- Universal Health Services, Inc. (UHS) $179.43
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $8.25B | $8.28B | $8.12B | $7.74B | $5.48B |
| Operating income | $1.01B | $1.1B | $956.2M | $795.2M | $378.5M |
| Net income | $229.3M | $791.5M | $612.3M | $505.3M | $153.2M |
| EPSd | $2.9M | $9.53M | $7.4M | $6.13M | $2.25M |
| Operating cash flow | $1.04B | $1.29B | $1.16B | $563.3M | $829.1M |
| Capital expenditure | -$-174.21M | -$-168.06M | -$-140.69M | -$-142.16M | -$-93.75M |
| Free cash flow | $862M | $1.12B | $1.02B | $421.2M | $735.4M |
| Total assets | $16.3B | $16.9B | $17B | $17.2B | $17.4B |
| Total debt | $3.56B | $3.6B | $3.94B | $4.83B | $5.65B |
| Net debt | $2.91B | $3.06B | $3.56B | $4.54B | $4.89B |
| Total equity | $9.19B | $9.52B | $9.24B | $8.5B | $8.07B |
| Cash and short-term investments | $647.3M | $538.8M | $380.1M | $290.5M | $753.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $8.25B | $8.28B | $8.12B | $7.74B | $5.48B |
| Cost of revenue | $6.08B | $5.85B | $5.72B | $5.53B | $3.97B |
| Gross profit | $2.18B | $2.44B | $2.4B | $2.21B | $1.51B |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $780.1M | $728.4M | $776.4M | $778.8M | $585.3M |
| Other expenses | $383M | $610.2M | $667.7M | $640.4M | $544.4M |
| Operating expenses | $1.16B | $1.34B | $1.44B | $1.42B | $1.13B |
| Cost and expenses | $7.24B | $7.18B | $7.16B | $6.95B | $5.1B |
| Interest income | $7.11M | $8.61M | $5.01M | $2.35M | $570K |
| Interest expense | $188.1M | $237.2M | $336.7M | $229.7M | $182.4M |
| Depreciation and amortization | $383M | $488.5M | $586M | $614.7M | $360.3M |
| Ebitda | $823.6M | $1.56B | $1.52B | $1.41B | $739.4M |
| Operating income | $1.01B | $1.1B | $956.2M | $795.2M | $378.5M |
| Total other income/expenses, net | -$-759.99M | -$-228.63M | -$-331.69M | -$-230.52M | -$-184.01M |
| Income before tax | $252.5M | $869.2M | $624.1M | $564.7M | $194.5M |
| Income tax expense | $23.1M | $77.7M | $11.8M | $59.4M | $41.3M |
| Net income | $229.3M | $791.5M | $612.3M | $505.3M | $153.2M |
| Weighted average shares outstanding | $78.4M | $82.5M | $82.1M | $81.5M | $67.1M |
| Weighted average diluted shares outstanding | $79M | $83M | $82.7M | $82.5M | $68.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $647.3M | $538.8M | $380.1M | $290.5M | $753.9M |
| Net receivables | $2.75B | $2.85B | $2.9B | $2.8B | $2.07B |
| Inventory | $0.00 | $0.00 | $0.00 | $7.06M | $0.00 |
| Total current assets | $3.5B | $3.53B | $3.41B | $3.23B | $2.94B |
| Property, plant and equipment, net | $524.7M | $530.5M | $501.5M | $504.2M | $534.6M |
| Goodwill and intangible assets | $12B | $12.6B | $12.9B | $13.3B | $13.7B |
| Long-term investments | $82.1M | $58M | $46.8M | $32.6M | $25M |
| Total non-current assets | $12.8B | $13.3B | $13.6B | $14B | $14.4B |
| Total assets | $16.3B | $16.9B | $17B | $17.2B | $17.4B |
| Accounts payable | $780.9M | $704.6M | $595.5M | $611.4M | $227M |
| Short-term debt | $566M | $66.6M | $146.6M | $98.8M | $105.1M |
| Deferred revenue | $1.55B | $1.61B | $1.65B | $1.51B | $1.32B |
| Total current liabilities | $3.2B | $2.8B | $2.83B | $2.69B | $2.48B |
| Long-term debt | $2.99B | $3.54B | $3.79B | $4.73B | $5.54B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $730K |
| Total non-current liabilities | $3.88B | $4.56B | $4.92B | $6B | $6.84B |
| Capital lease obligations | $153.4M | $176.9M | $162.7M | $175.3M | $209.4M |
| Total liabilities | $7.08B | $7.35B | $7.75B | $8.69B | $9.32B |
| Common stock | $6.3M | $6.59M | $6.7M | $6.65M | $6.64M |
| Retained earnings | $2.12B | $2.72B | $2.43B | $1.82B | $1.42B |
| Accumulated other comprehensive income (loss) | -$-68.53M | -$-228.62M | -$-142.34M | -$-171.54M | -$-90.94M |
| Total equity | $9.19B | $9.52B | $9.24B | $8.5B | $8.07B |
| Total investments | $82.1M | $58M | $48.8M | $34.3M | $26.7M |
| Total debt | $3.56B | $3.6B | $3.94B | $4.83B | $5.65B |
| Net debt | $2.91B | $3.06B | $3.56B | $4.54B | $4.89B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $229.3M | $791.5M | $612.3M | $505.3M | $153.2M |
| Depreciation and amortization | $383M | $528.3M | $586M | $569.5M | $315M |
| Stock-based compensation | $102M | $45.9M | $55.7M | $70.5M | $133.8M |
| Change in working capital | -$-98.1M | -$-56.51M | -$-114.82M | -$-550.22M | $135M |
| Accounts receivable | -$-169.32M | $9.39M | -$-78.58M | -$-753.29M | $95.9M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $1.04B | $1.29B | $1.16B | $563.3M | $829.1M |
| Investments in property, plant and equipment | -$-174.21M | -$-168.06M | -$-140.69M | -$-142.16M | -$-93.75M |
| Acquisitions, net | -$-2.54M | -$-84.16M | -$-71.77M | -$-1.91M | -$-5.92B |
| Net cash used for investing activities | -$-187.53M | -$-266.79M | -$-226.65M | -$-145.87M | -$-6.02B |
| Common stock issued | $9.72M | $36.2M | $51M | $35.8M | $117.7M |
| Common stock repurchased | -$-750M | -$-500M | $0.00 | -$-99.98M | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-771.26M | -$-837.18M | -$-844.04M | -$-864.17M | $5.11B |
| Net change in cash | $108.5M | $160.7M | $89.3M | -$-463.44M | -$-88.09M |
| Cash at end of period | $647.3M | $538.8M | $378.1M | $288.8M | $752.2M |
| Operating cash flow | $1.04B | $1.29B | $1.16B | $563.3M | $829.1M |
| Capital expenditure | -$-174.21M | -$-168.06M | -$-140.69M | -$-142.16M | -$-93.75M |
| Free cash flow | $862M | $1.12B | $1.02B | $421.2M | $735.4M |
Line items
Line items
Line items
About ICON Public Limited Company
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
- CEO
- Barry Balfe
- Employees
- 40.35K
- Beta
- 1.22
Explore
Frequently asked questions
What is the intrinsic value of ICON Public Limited Company (ICLR)?
ICON Public Limited Company (ICLR) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ICLR undervalued?
ICLR trades at a price of $186.71 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.